PacBio Q3 revenue $55.7M (+72% YoY); net loss narrows to $66.9M

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

2023-Q3 EPS reported -$0.90 revenue$142,164,000

Revenue $55.7M, up 72% YoY; instrument revenue $34.7M from 52 Revio systems (prior year $11.4M).
Consumables revenue $16.9M (record; +5% YoY) with Revio consumables surpassing Sequel II/IIe.
GAAP net loss $66.9M ($0.26/shr) vs $77.0M ($0.34/shr) prior year; Non-GAAP net loss $67.9M ($0.27).
Gross margin 32% vs 42% prior year; non-GAAP gross margin also 32%.
Cash and investments $767.8M; launched leasing program, first Onso shipments, and new WGS variant pipeline.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the quarter ended September 30, 2023 results: revenue $55.7 million, net income Net loss for the third quarter of 2023 was $66.9 million, EPS $0.26.

Period: the quarter ended September 30, 2023
Revenue: $55.7 million
Net income: Net loss for the third quarter of 2023 was $66.9 million
EPS: $0.26
Result: reported results

Exact text from the filing

PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2023. Third quarter results • Revenue of $55.7 million

View on SEC.gov

Browse all earnings releases →

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. filing history →

Source: SEC EDGAR

accession 0001299130-23-000135

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.